Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma

• Sponsor: Abramson Cancer Center of the University of Pennsylvania (Other)
• Overall Status: Completed
• CT.gov ID: NCT00602576
• Collaborator: National Cancer Institute (NCI) (NIH)
• Enrollment: 169
• Location: 1
• Arms: 4
• Actual Duration (Months): 54.8
• Patients Per Site Per Month: 3.1

Study Details

Study Description

Brief Summary

RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving temozolomide together with sorafenib may kill more tumor cells.

PURPOSE: This randomized phase II trial is studying two different schedules of temozolomide when given together with sorafenib to compare how well they work in treating patients with metastatic or unresectable melanoma.

Condition or Disease	Intervention/Treatment	Phase
Melanoma (Skin)	Drug: sorafenib tosylate; Drug: temozolomide	Phase 2

Detailed Description

OBJECTIVES:

Primary

• To measure the progression-free survival of patients with metastatic or unresectable melanoma with no brain metastasis or no prior treatment with temozolomide (TMZ) treated with sorafenib tosylate in combination with two different schedules (extended daily dosing vs standard dosing) of TMZ.

• To measure the progression-free survival of patients with or without brain metastasis and prior treatment with TMZ treated with sorafenib in combination with extended daily dosing of TMZ.

• To measure the progression-free survival of patients with brain metastasis and no prior treatment with TMZ treated with sorafenib in combination with standard dosing TMZ.

• To estimate the median time to progression in all patients.

• To quantify the number and percent of patients who have stable disease after 6 months of treatment (failure to progress).

• To choose the optimal combination dosing regimen for further study.

Secondary

• To estimate and define the objective response rate in these patients.

• To characterize the duration of objective responses in these patients.

• To estimate the incidence of new symptomatic brain metastasis in these patients.

• To measure overall survival of these patients.

OUTLINE: This is a multicenter study. Patients are stratified according to prior brain metastases (yes vs no) and prior treatment with temozolomide (TMZ) (yes vs no). Patients with no prior brain metastases who did not receive prior treatment with TMZ are randomized to 1 of 2 treatment arms. These patients are further stratified according to prior treatment with sorafenib tosylate (yes vs no). Patients with or without prior brain metastases who received prior treatment with TMZ are assigned to arm I. Patients with prior brain metastases who did not receive prior treatment with TMZ are assigned to arm II.

• Arm I: Patients receive oral sorafenib tosylate twice daily on days -7 to 56 of course 1 and on days 1-56 of all subsequent courses. Patients also receive oral TMZ once daily on days 1-42.

• Arm II: Patients receive sorafenib tosylate as in arm I and oral TMZ once daily on days 1-5 and 29-33.

In both arms, courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.

Study Design

• Study Type: Interventional
• Actual Enrollment: 169 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: 4 arm parallel phase II study Arms A and B are randomized to different schedules of temozolomide Arm C is prior temozolomide-refractory patients Arm D is brain metastases patients4 arm parallel phase II study Arms A and B are randomized to different schedules of temozolomide Arm C is prior temozolomide-refractory patients Arm D is brain metastases patients
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Randomized Phase II Study Comparing Two Schedules Of Temozolomide In Combination With Bay 43-9006 In Patients With Advanced Melanoma
• Actual Study Start Date: Jan 1, 2005
• Actual Primary Completion Date: Dec 21, 2008
• Actual Study Completion Date: Jul 26, 2009

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Arm A Patients who were temozolomide naive and had no brain metastases received oral sorafenib tosylate twice daily on days -7 to 56 of course 1 and on days 1-56 of all subsequent courses. Patients also receive oral TMZ once daily on days 1-42.	Drug: sorafenib tosylate; Given orally; Other Names: nexavar ; Drug: temozolomide; Given orally; Other Names: temodar
Experimental: Arm B Patients who were temozolomide naive and had no brain metastases received sorafenib tosylate as in arm A and oral TMZ once daily on days 1-5 and 29-33.	Drug: sorafenib tosylate; Given orally; Other Names: nexavar ; Drug: temozolomide; Given orally; Other Names: temodar
Experimental: Arm C Patient with or without treated brain metastases who were treated with prior temozolomide and progressed were treated with oral sorafenib tosylate twice daily on days -7 to 56 of course 1 and on days 1-56 of all subsequent courses. Patients also receive oral TMZ once daily on days 1-42.	Drug: sorafenib tosylate; Given orally; Other Names: nexavar ; Drug: temozolomide; Given orally; Other Names: temodar
Experimental: Arm D Patients with treated brain metastases were treated with sorafenib tosylate as in arm B and oral TMZ once daily on days 1-5 and 29-33.	Drug: sorafenib tosylate; Given orally; Other Names: nexavar ; Drug: temozolomide; Given orally; Other Names: temodar

Outcome Measures

Primary Outcome Measures

1. Rate of 6 Month Progression-Free Survival [6 months]

   Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions

Secondary Outcome Measures

1. Response Rate [Approximately 3 years]

   Response Rate as defined by Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

2. Overall Survival Rate [1 year]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 120 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

INCLUSION CRITERIA:

1. Histologically or cytologically confirmed melanoma that is metastatic or unresectable.

2. The following groups are eligible with regard to prior therapy in either the adjuvant or metastatic disease setting:

1. No prior therapy c) Immunotherapy consisting of Interferon, Interleukin-2 or GM-CSF. d) Chemotherapy, either single-agent or combination. Prior temozolomide is allowable e) Vaccine therapy f) Prior sorafenib is allowable

NB: There is no limit on the number of prior therapies

1. Prior radiation therapy is allowed. However, if radiation has been administered to a lesion, there must be radiographic evidence of progression of that lesion in order for that lesion to constitute measurable disease or to be included in the measured target lesions.

2. Measurable disease by RECIST criteria. Cutaneous lesions measuring at least 1 cm will be considered. Baseline CT or MRI scans of disease sites must be performed within 4 weeks of study entry. For patients with bone metastases, a baseline bone scan must be performed within 4 weeks of study entry.

3. Age > 18 years.

4. Eastern Cooperative Oncology Group performance status of 0 or 1.

5. Baseline laboratory values (evaluated within 14 days of randomization):

White Blood Count > 3,000/mm3 Absolute Granulocyte Count > 1,500/mm3 Platelet Count > 100,000/mm3 Serum creatinine < 2.0 x upper limit of normal (ULN) or serum creatinine clearance estimated by the MDRD formula Total Bilirubin < 1.5 x ULN (< 3.0 x ULN in the presence of Gilbert's disease AST/ALT < 2.5 x ULN (< 5.0 ULN in the presence of liver metastases) INR < 1.5 and a PTT within the upper limit of normal (if on anticoagulation baseline INR before starting anticoagulation must be <1.5)

1. Patients must have discontinued active immunotherapy (IL-2, interferon, CTLA-4, etc.) or chemotherapy at least 4 weeks prior to entering the study and recovered from adverse events due to those agents. Patients must not receive any other investigational anticancer therapy during the period on study or the four weeks prior to entry, with the exception of vaccines.

2. Patients with brain metastases must have completed radiation therapy if radiation is clinically indicated at the time of diagnosis and discontinued steroids prior to enrollment.

3. The effects of sorafenib, temozolomide on the developing human fetus are unknown. For this reason and because antiangiogenic agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant while participating in this study, she should inform her treating physician immediately. If a man impregnates a woman while participatig in this study, he should inform his treating physician immediately as well.

EXCLUSION CRITERIA

1. Patients must not have other current malignancies, other than basal cell skin cancer, squamous cell skin cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast.

2. Patients must not have a serious intercurrent illness including, but not limited to, ongoing or active infection requiring parental antibiotics, clinically significant cardiovascular disease (e.g. uncontrolled hypertension, myocardial infarction, unstable angina), New York heart association grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication, or grade II or greater peripheral vascular disease within 1 year prior to study entry, or psychiatric illness/social situations that would limit compliance with study requirements.

3. Patients must not be taking cytochrome P450 enzyme-inducing antiepileptic drugs (phenytoin, carbamazepine or phenobarbital), rifampin or St. John's wort.

4. Women must not be pregnant or breast-feeding as the agents used in this study may be teratogenic to a fetus and there is no information on the excretion of the agents or their metabolites into breast milk. All females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy.

5. Because patients with immune deficiency are at increased risk of lethal infections when treated with bone marrow-suppressive therapy, HIV-positive patients are excluded from the study. For patients receiving combination anti-retroviral therapy, the potential impact of pharmacokinetic interactions with sorafenib, temozolomide is unknown. Appropriate studies may be undertaken in patients with HIV and those receiving combination anti-retroviral therapy in the future.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Abramson Cancer Center of the University of Pennsylvania	Philadelphia	Pennsylvania	United States	19104-4283

Sponsors and Collaborators

• Abramson Cancer Center of the University of Pennsylvania
• National Cancer Institute (NCI)

Investigators

• Principal Investigator: Ravi Amaravadi, MD, Abramson Cancer Center of the University of Pennsylvania

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Abramson Cancer Center of the University of Pennsylvania
• ClinicalTrials.gov Identifier: NCT00602576
• Other Study ID Numbers: CDR0000580808; 06604; 802514; P30CA016520
• First Posted: Jan 28, 2008
• Last Update Posted: Jun 14, 2022
• Last Verified: Jun 1, 2022

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Abramson Cancer Center of the University of Pennsylvania: recurrent melanoma; stage III melanoma; stage IV melanoma
• Additional relevant MeSH terms: Melanoma; Temozolomide; Sorafenib

Study Results

Participant Flow

Arm/Group Title	Arm A	Arm B	Arm C	Arm D
Arm/Group Description	Patients who were temozolomide naive and had no brain metastases received oral sorafenib tosylate twice daily on days -7 to 56 of course 1 and on days 1-56 of all subsequent courses. Patients also receive oral TMZ once daily on days 1-42. sorafenib tosylate: Given orally temozolomide: Given orally	Patients who were temozolomide naive and had no brain metastases received sorafenib tosylate as in arm A and oral TMZ once daily on days 1-5 and 29-33. sorafenib tosylate: Given orally temozolomide: Given orally	Patient with or without treated brain metastases who were treated with prior temozolomide and progressed were treated with oral sorafenib tosylate twice daily on days -7 to 56 of course 1 and on days 1-56 of all subsequent courses. Patients also receive oral TMZ once daily on days 1-42. sorafenib tosylate: Given orally temozolomide: Given orally	Patients with treated brain metastases were treated with sorafenib tosylate as in arm B and oral TMZ once daily on days 1-5 and 29-33. sorafenib tosylate: Given orally temozolomide: Given orally
Period Title: Overall Study
STARTED	38	40	38	53
COMPLETED	38	40	38	53
NOT COMPLETED	0	0	0	0

Baseline Characteristics

Arm/Group Title	Arm A	Arm B	Arm C	Arm D	Total
Arm/Group Description	Patients who were temozolomide naive and had no brain metastases received oral sorafenib tosylate twice daily on days -7 to 56 of course 1 and on days 1-56 of all subsequent courses. Patients also receive oral TMZ once daily on days 1-42. sorafenib tosylate: Given orally temozolomide: Given orally	Patients who were temozolomide naive and had no brain metastases received sorafenib tosylate as in arm A and oral TMZ once daily on days 1-5 and 29-33. sorafenib tosylate: Given orally temozolomide: Given orally	Patient with or without treated brain metastases who were treated with prior temozolomide and progressed were treated with oral sorafenib tosylate twice daily on days -7 to 56 of course 1 and on days 1-56 of all subsequent courses. Patients also receive oral TMZ once daily on days 1-42. sorafenib tosylate: Given orally temozolomide: Given orally	Patients with treated brain metastases were treated with sorafenib tosylate as in arm B and oral TMZ once daily on days 1-5 and 29-33. sorafenib tosylate: Given orally temozolomide: Given orally	Total of all reporting groups
Overall Participants	38	40	38	53	169
Age (years) [Median (Full Range) ]
Median (Full Range) [years]	62	61	61	58	61
Sex: Female, Male (Count of Participants)
Female	16 42.1%	10 25%	10 26.3%	18 34%	54 32%
Male	22 57.9%	30 75%	28 73.7%	35 66%	115 68%
Race and Ethnicity Not Collected (Count of Participants)
Count of Participants [Participants]	0 0%
Region of Enrollment (participants) [Number]
United States	38 100%	40 100%	38 100%	53 100%	169 100%

Outcome Measures

1. Primary Outcome

Title	Rate of 6 Month Progression-Free Survival
Description	Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions
Time Frame	6 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Arm A	Arm B	Arm C	Arm D
Arm/Group Description	Patients who were temozolomide naive and had no brain metastases received oral sorafenib tosylate twice daily on days -7 to 56 of course 1 and on days 1-56 of all subsequent courses. Patients also receive oral TMZ once daily on days 1-42. sorafenib tosylate: Given orally temozolomide: Given orally	Patients who were temozolomide naive and had no brain metastases received sorafenib tosylate as in arm A and oral TMZ once daily on days 1-5 and 29-33. sorafenib tosylate: Given orally temozolomide: Given orally	Patient with or without treated brain metastases who were treated with prior temozolomide and progressed were treated with oral sorafenib tosylate twice daily on days -7 to 56 of course 1 and on days 1-56 of all subsequent courses. Patients also receive oral TMZ once daily on days 1-42. sorafenib tosylate: Given orally temozolomide: Given orally	Patients with treated brain metastases were treated with sorafenib tosylate as in arm B and oral TMZ once daily on days 1-5 and 29-33. sorafenib tosylate: Given orally temozolomide: Given orally
Measure Participants	38	40	38	53
Count of Participants [Participants]	18 47.4%	15 37.5%	4 10.5%	12 22.6%

2. Secondary Outcome

Title	Response Rate
Description	Response Rate as defined by Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Time Frame	Approximately 3 years

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Arm A	Arm B	Arm C	Arm D
Arm/Group Description	Patients who were temozolomide naive and had no brain metastases received oral sorafenib tosylate twice daily on days -7 to 56 of course 1 and on days 1-56 of all subsequent courses. Patients also receive oral TMZ once daily on days 1-42. sorafenib tosylate: Given orally temozolomide: Given orally	Patients who were temozolomide naive and had no brain metastases received sorafenib tosylate as in arm A and oral TMZ once daily on days 1-5 and 29-33. sorafenib tosylate: Given orally temozolomide: Given orally	Patient with or without treated brain metastases who were treated with prior temozolomide and progressed were treated with oral sorafenib tosylate twice daily on days -7 to 56 of course 1 and on days 1-56 of all subsequent courses. Patients also receive oral TMZ once daily on days 1-42. sorafenib tosylate: Given orally temozolomide: Given orally	Patients with treated brain metastases were treated with sorafenib tosylate as in arm B and oral TMZ once daily on days 1-5 and 29-33. sorafenib tosylate: Given orally temozolomide: Given orally
Measure Participants	38	40	38	53
Count of Participants [Participants]	8 21.1%	6 15%	0 0%	8 15.1%

3. Secondary Outcome

Title	Overall Survival Rate
Time Frame	1 year

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Arm A	Arm B	Arm C	Arm D
Arm/Group Description	Patients who were temozolomide naive and had no brain metastases received oral sorafenib tosylate twice daily on days -7 to 56 of course 1 and on days 1-56 of all subsequent courses. Patients also receive oral TMZ once daily on days 1-42. sorafenib tosylate: Given orally temozolomide: Given orally	Patients who were temozolomide naive and had no brain metastases received sorafenib tosylate as in arm A and oral TMZ once daily on days 1-5 and 29-33. sorafenib tosylate: Given orally temozolomide: Given orally	Patient with or without treated brain metastases who were treated with prior temozolomide and progressed were treated with oral sorafenib tosylate twice daily on days -7 to 56 of course 1 and on days 1-56 of all subsequent courses. Patients also receive oral TMZ once daily on days 1-42. sorafenib tosylate: Given orally temozolomide: Given orally	Patients with treated brain metastases were treated with sorafenib tosylate as in arm B and oral TMZ once daily on days 1-5 and 29-33. sorafenib tosylate: Given orally temozolomide: Given orally
Measure Participants	38	40	38	53
Count of Participants [Participants]	12 31.6%	18 45%	5 13.2%	17 32.1%

Adverse Events

Time Frame	4 years
Adverse Event Reporting Description	the definition ofadverse event and serious adverse events were according to clinicaltrials.gov definitions
Arm/Group Title	Arm A		Arm B		Arm C		Arm D
Arm/Group Description	Patients who were temozolomide naive and had no brain metastases received oral sorafenib tosylate twice daily on days -7 to 56 of course 1 and on days 1-56 of all subsequent courses. Patients also receive oral TMZ once daily on days 1-42. sorafenib tosylate: Given orally temozolomide: Given orally		Patients who were temozolomide naive and had no brain metastases received sorafenib tosylate as in arm A and oral TMZ once daily on days 1-5 and 29-33. sorafenib tosylate: Given orally temozolomide: Given orally		Patient with or without treated brain metastases who were treated with prior temozolomide and progressed were treated with oral sorafenib tosylate twice daily on days -7 to 56 of course 1 and on days 1-56 of all subsequent courses. Patients also receive oral TMZ once daily on days 1-42. sorafenib tosylate: Given orally temozolomide: Given orally		Patients with treated brain metastases were treated with sorafenib tosylate as in arm B and oral TMZ once daily on days 1-5 and 29-33. sorafenib tosylate: Given orally temozolomide: Given orally
All Cause Mortality
	Arm A		Arm B		Arm C		Arm D
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	/ (NaN)		/ (NaN)		/ (NaN)		/ (NaN)
Serious Adverse Events
	Arm A		Arm B		Arm C		Arm D
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	2/38 (5.3%)		0/40 (0%)		4/38 (10.5%)		1/53 (1.9%)
Gastrointestinal disorders
constipation	1/38 (2.6%)	1	0/40 (0%)	0	0/38 (0%)	0	0/53 (0%)	0
GI perforation	0/38 (0%)	0	0/40 (0%)	0	1/38 (2.6%)	1	0/53 (0%)	0
General disorders
dehydration	0/38 (0%)	0	0/40 (0%)	0	0/38 (0%)	0	1/53 (1.9%)	1
Metabolism and nutrition disorders
delayed wound healing	1/38 (2.6%)	1	0/40 (0%)	0	0/38 (0%)	0	0/53 (0%)	0
Vascular disorders
CNS hemorrhage	0/38 (0%)	0	0/40 (0%)	0	1/38 (2.6%)	1	0/53 (0%)	0
Pulmonary embolism	0/38 (0%)	0	0/40 (0%)	0	1/38 (2.6%)	1	0/53 (0%)	0
aterial thrombus	0/38 (0%)	0	0/40 (0%)	0	1/38 (2.6%)	1	0/53 (0%)	0
Other (Not Including Serious) Adverse Events
	Arm A		Arm B		Arm C		Arm D
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	38/38 (100%)		40/40 (100%)		38/38 (100%)		53/53 (100%)
Blood and lymphatic system disorders
anemia	13/38 (34.2%)	13	20/40 (50%)	20	9/38 (23.7%)	9	16/53 (30.2%)	16
lymphopenia	30/38 (78.9%)	30	27/40 (67.5%)	27	28/38 (73.7%)	28	34/53 (64.2%)	34
neutropenia	13/38 (34.2%)	13	6/40 (15%)	6	2/38 (5.3%)	2	5/53 (9.4%)	5
Thrombocytopenia	14/38 (36.8%)	14	9/40 (22.5%)	9	9/38 (23.7%)	9	17/53 (32.1%)	17
Cardiac disorders
hypertension	11/38 (28.9%)	11	5/40 (12.5%)	5	6/38 (15.8%)	6	14/53 (26.4%)	14
Gastrointestinal disorders
abdominal pain	7/38 (18.4%)	7	5/40 (12.5%)	5	2/38 (5.3%)	2	6/53 (11.3%)	6
Constipation	21/38 (55.3%)	21	12/40 (30%)	12	9/38 (23.7%)	9	16/53 (30.2%)	16
Diarrhea	23/38 (60.5%)	23	19/40 (47.5%)	19	7/38 (18.4%)	7	29/53 (54.7%)	29
Nausea	27/38 (71.1%)	27	30/40 (75%)	30	21/38 (55.3%)	21	31/53 (58.5%)	31
General disorders
Fatigue	30/38 (78.9%)	30	29/40 (72.5%)	29	22/38 (57.9%)	22	39/53 (73.6%)	39
hoarseness	6/38 (15.8%)	6	7/40 (17.5%)	7	6/38 (15.8%)	6	9/53 (17%)	9
Metabolism and nutrition disorders
anorexia	25/38 (65.8%)	25	22/40 (55%)	22	18/38 (47.4%)	18	28/53 (52.8%)	28
dehydration	4/38 (10.5%)	4	3/40 (7.5%)	3	2/38 (5.3%)	2	7/53 (13.2%)	7
Weight loss	24/38 (63.2%)	24	22/40 (55%)	22	14/38 (36.8%)	14	29/53 (54.7%)	29
Musculoskeletal and connective tissue disorders
Myalgia	13/38 (34.2%)	13	10/40 (25%)	10	10/38 (26.3%)	10	12/53 (22.6%)	12
Nervous system disorders
Headache	7/38 (18.4%)	7	6/40 (15%)	6	4/38 (10.5%)	4	2/53 (3.8%)	2
Skin and subcutaneous tissue disorders
alopecia	23/38 (60.5%)	23	16/40 (40%)	16	5/38 (13.2%)	5	16/53 (30.2%)	16
Hand/foot syndrome	27/38 (71.1%)	27	29/40 (72.5%)	29	17/38 (44.7%)	17	34/53 (64.2%)	34
Rash	33/38 (86.8%)	33	34/40 (85%)	34	19/38 (50%)	19	33/53 (62.3%)	33
stomatitis	18/38 (47.4%)	18	15/40 (37.5%)	15	15/38 (39.5%)	15	25/53 (47.2%)	25

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.